Jpmorgan Chase & CO Acadia Pharmaceuticals Inc Transaction History

Jpmorgan Chase & CO

$1.23 Trillion
Q4 2024

A detailed history of Jpmorgan Chase & CO transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 713,360 shares of ACAD stock, worth $12.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

713,360

Previous 441,124 61.71%

Holding current value

$12.9 Million

Previous $6.79 Million 92.84%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$14.29 - $18.76 $3.89 Million - $5.11 Million	272,236 Added 61.71%	713,360 $13.1 Million
Q3 2024 Dec 26, 2024	SELL	$15.14 - $19.14 $2.83 Million - $3.58 Million	-187,125 Reduced 29.79%	441,124 $6.79 Million
Q3 2024 Nov 08, 2024	SELL	$15.14 - $19.14 $2.83 Million - $3.58 Million	-187,125 Reduced 29.79%	441,124 $6.79 Million
Q2 2024 Dec 26, 2024	BUY	$14.62 - $18.42 $2.74 Million - $3.45 Million	187,125 Added 42.42%	628,249 $10.2 Million
Q2 2024 Aug 12, 2024	BUY	$14.62 - $18.42 $2.24 Million - $2.82 Million	153,245 Added 32.26%	628,249 $10.2 Million
Q1 2024 Dec 26, 2024	BUY	$17.79 - $30.86 $602,725 - $1.05 Million	33,880 Added 7.68%	475,004 $8.78 Million
Q1 2024 May 10, 2024	SELL	$17.79 - $30.86 $3.31 Million - $5.74 Million	-185,896 Reduced 28.13%	475,004 $8.78 Million
Q4 2023 Dec 26, 2024	BUY	$20.78 - $31.77 $4.57 Million - $6.98 Million	219,776 Added 49.82%	660,900 $20.7 Million
Q4 2023 Feb 12, 2024	BUY	$20.78 - $31.77 $4.22 Million - $6.45 Million	202,985 Added 44.33%	660,900 $20.7 Million
Q3 2023 Nov 14, 2023	BUY	$20.84 - $33.47 $3.69 Million - $5.92 Million	176,923 Added 62.96%	457,915 $9.54 Million
Q2 2023 Aug 11, 2023	SELL	$17.8 - $25.65 $23.2 Million - $33.4 Million	-1,303,792 Reduced 82.27%	280,992 $6.73 Million
Q1 2023 May 18, 2023	BUY	$16.32 - $20.92 $2.6 Million - $3.33 Million	159,068 Added 11.16%	1,584,784 $29.8 Million
Q1 2023 May 11, 2023	SELL	$16.32 - $20.92 $10.9 Million - $14 Million	-669,775 Reduced 31.96%	1,425,716 $26.8 Million
Q4 2022 Feb 13, 2023	BUY	$14.2 - $18.63 $3.36 Million - $4.41 Million	236,530 Added 12.72%	2,095,491 $33.4 Million
Q3 2022 Nov 14, 2022	SELL	$14.11 - $18.27 $673,879 - $872,556	-47,759 Reduced 2.5%	1,858,961 $30.4 Million
Q2 2022 Aug 11, 2022	SELL	$13.01 - $27.22 $5.25 Million - $11 Million	-403,635 Reduced 17.47%	1,906,720 $26.9 Million
Q1 2022 May 11, 2022	BUY	$20.94 - $27.5 $2.27 Million - $2.97 Million	108,179 Added 4.91%	2,310,355 $56 Million
Q4 2021 Feb 10, 2022	SELL	$16.79 - $27.09 $1.9 Million - $3.07 Million	-113,440 Reduced 4.9%	2,202,176 $51.4 Million
Q3 2021 Nov 12, 2021	BUY	$15.78 - $24.77 $36.5 Million - $57.4 Million	2,315,616 New	2,315,616 $38.5 Million

Others Institutions Holding ACAD

# of Institutions

316

Shares Held

164M

Call Options Held

855K

Put Options Held

350K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.93B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Acadia Pharmaceuticals Inc Transaction History